RESUMEN
Over the past several centuries, the integration of contemporary medical techniques and innovative technologies, like genetic sequencing, have played a pivotal role in enhancing our comprehension of congenital vascular and lymphatic disorders. Nonetheless, the uncommon and complex characteristics of these disorders, especially considering their formation during the intrauterine stage, present significant obstacles in diagnosis and treatment. Here, we review the intricacies of these congenital abnormalities, offering an in-depth examination of key diagnostic approaches, genetic factors, and therapeutic methods.
Asunto(s)
Enfermedades Linfáticas , Humanos , Enfermedades Linfáticas/terapia , Enfermedades Linfáticas/genética , Enfermedades Vasculares/congénito , Enfermedades Vasculares/genética , Enfermedades Vasculares/terapia , Enfermedades Vasculares/diagnóstico , Animales , Malformaciones Vasculares/genética , Malformaciones Vasculares/terapia , Vasos Linfáticos/anomalías , Predisposición Genética a la EnfermedadAsunto(s)
Canalopatías , Linfangiectasia Intestinal , Vasos Linfáticos , Linfedema , Cationes , Canalopatías/genética , Anomalías Craneofaciales , HumanosRESUMEN
Vascular malformations, affecting ≈1% to 1.5% of the population, comprise a spectrum of developmental patterning defects of capillaries, arteries, veins, and/or lymphatics. The majority of vascular malformations occur sporadically; however, inherited malformations exist as a part of complex congenital diseases. The malformations, ranging from birthmarks to life-threatening conditions, are present at birth, but may reveal signs and symptoms-including pain, bleeding, disfigurement, and functional defects of vital organs-in infancy, childhood, or adulthood. Vascular malformations often exhibit recurrent patterns at affected sites due to the lack of curative treatments. This review series provides a state-of-the-art assessment of vascular malformation research at basic, clinical, genetic, and translational levels.
Asunto(s)
Vasos Sanguíneos/anomalías , Anomalías Linfáticas , Vasos Linfáticos/anomalías , Malformaciones Vasculares , Animales , Vasos Sanguíneos/metabolismo , Predisposición Genética a la Enfermedad , Variación Genética , Humanos , Anomalías Linfáticas/genética , Anomalías Linfáticas/metabolismo , Anomalías Linfáticas/patología , Anomalías Linfáticas/terapia , Vasos Linfáticos/metabolismo , Fenotipo , Factores de Riesgo , Malformaciones Vasculares/genética , Malformaciones Vasculares/metabolismo , Malformaciones Vasculares/patología , Malformaciones Vasculares/terapiaAsunto(s)
Proteínas Adaptadoras Transductoras de Señales/metabolismo , Transformación Celular Neoplásica/metabolismo , Células Endoteliales/metabolismo , Hemangioendotelioma Epitelioide/metabolismo , Neoplasias Vasculares/metabolismo , Proteínas Adaptadoras Transductoras de Señales/genética , Animales , Antígenos CD/genética , Antígenos CD/metabolismo , Cadherinas/genética , Cadherinas/metabolismo , Transformación Celular Neoplásica/genética , Transformación Celular Neoplásica/patología , Células Endoteliales/patología , Regulación Neoplásica de la Expresión Génica , Hemangioendotelioma Epitelioide/genética , Hemangioendotelioma Epitelioide/patología , Humanos , Ratones Transgénicos , Transducción de Señal , Factores de Transcripción/genética , Factores de Transcripción/metabolismo , Neoplasias Vasculares/genética , Neoplasias Vasculares/patología , Proteínas Señalizadoras YAPRESUMEN
Huntington's disease pathogenesis involves a genetic gain-of-function toxicity mechanism triggered by the expanded HTT CAG repeat. Current therapeutic efforts aim to suppress expression of total or mutant huntingtin, though the relationship of huntingtin's normal activities to the gain-of-function mechanism and what the effects of huntingtin-lowering might be are unclear. Here, we have re-investigated a rare family segregating two presumed HTT loss-of-function (LoF) variants associated with the developmental disorder, Lopes-Maciel-Rodan syndrome (LOMARS), using whole-genome sequencing of DNA from cell lines, in conjunction with analysis of mRNA and protein expression. Our findings correct the muddled annotation of these HTT variants, reaffirm they are the genetic cause of the LOMARS phenotype and demonstrate that each variant is a huntingtin hypomorphic mutation. The NM_002111.8: c.4469+1G>A splice donor variant results in aberrant (exon 34) splicing and severely reduced mRNA, whereas, surprisingly, the NM_002111.8: c.8157T>A NP_002102.4: Phe2719Leu missense variant results in abnormally rapid turnover of the Leu2719 huntingtin protein. Thus, although rare and subject to an as yet unknown LoF intolerance at the population level, bona fide HTT LoF variants can be transmitted by normal individuals leading to severe consequences in compound heterozygotes due to huntingtin deficiency.
Asunto(s)
Regulación de la Expresión Génica , Proteína Huntingtina/genética , Mutación , Trastornos del Neurodesarrollo/genética , Secuencia de Aminoácidos , Línea Celular , Niño , Preescolar , Femenino , Humanos , Proteína Huntingtina/química , Proteína Huntingtina/metabolismo , Mutación con Pérdida de Función , Masculino , Mutación Missense , Trastornos del Neurodesarrollo/metabolismo , Linaje , Fenotipo , Empalme del ARN , ARN Mensajero/genética , ARN Mensajero/metabolismo , Alineación de Secuencia , Análisis de Secuencia de ADNRESUMEN
The polyQ expansion in huntingtin protein (HTT) is the prime cause of Huntington's disease (HD). The recent cryoelectron microscopy (cryo-EM) structure of HTT-HAP40 complex provided the structural information on its HEAT-repeat domains. Here, we present analyses of the impact of polyQ length on the structure and function of HTT via an integrative structural and biochemical approach. The cryo-EM analysis of normal (Q23) and disease (Q78) type HTTs shows that the structures of apo HTTs significantly differ from the structure of HTT in a HAP40 complex and that the polyQ expansion induces global structural changes in the relative movements among the HTT domains. In addition, we show that the polyQ expansion alters the phosphorylation pattern across HTT and that Ser2116 phosphorylation in turn affects the global structure and function of HTT. These results provide a molecular basis for the effect of the polyQ segment on HTT structure and activity, which may be important for HTT pathology.
Asunto(s)
Proteína Huntingtina/química , Proteína Huntingtina/metabolismo , Péptidos/metabolismo , Microscopía por Crioelectrón , Humanos , Proteína Huntingtina/genética , Espectrometría de Masas de Intercambio de Hidrógeno-Deuterio , Espectrometría de Masas , Modelos Moleculares , Mutación , Péptidos/química , Fosforilación , Dominios Proteicos , Dispersión del Ángulo Pequeño , Serina/metabolismo , Difracción de Rayos XRESUMEN
The CAG repeat expansion that elongates the polyglutamine tract in huntingtin is the root genetic cause of Huntington's disease (HD), a debilitating neurodegenerative disorder. This seemingly slight change to the primary amino acid sequence alters the physical structure of the mutant protein and alters its activity. We have identified a set of G-quadruplex-forming DNA aptamers (MS1, MS2, MS3, MS4) that bind mutant huntingtin proximal to lysines K2932/K2934 in the C-terminal CTD-II domain. Aptamer binding to mutant huntingtin abrogated the enhanced polycomb repressive complex 2 (PRC2) stimulatory activity conferred by the expanded polyglutamine tract. In HD, but not normal, neuronal progenitor cells (NPCs), MS3 aptamer co-localized with endogenous mutant huntingtin and was associated with significantly decreased PRC2 activity. Furthermore, MS3 transfection protected HD NPCs against starvation-dependent stress with increased ATP. Therefore, DNA aptamers can preferentially target mutant huntingtin and modulate a gain of function endowed by the elongated polyglutamine segment. These mutant huntingtin binding aptamers provide novel molecular tools for delineating the effects of the HD mutation and encourage mutant huntingtin structure-based approaches to therapeutic development.
RESUMEN
The polyglutamine expansion in huntingtin protein causes Huntington's disease. Here, we investigated structural and biochemical properties of huntingtin and the effect of the polyglutamine expansion using various biophysical experiments including circular dichroism, single-particle electron microscopy and cross-linking mass spectrometry. Huntingtin is likely composed of five distinct domains and adopts a spherical α-helical solenoid where the amino-terminal and carboxyl-terminal regions fold to contain a circumscribed central cavity. Interestingly, we showed that the polyglutamine expansion increases α-helical properties of huntingtin and affects the intramolecular interactions among the domains. Our work delineates the structural characteristics of full-length huntingtin, which are affected by the polyglutamine expansion, and provides an elegant solution to the apparent conundrum of how the extreme amino-terminal polyglutamine tract confers a novel property on huntingtin, causing the disease.